GlobeNewswire by notified

AB Klaipėdos nafta unaudited financial information regarding the three months of 2022


AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and standalone financial results for three months ended 31 March 2022.

Main financial indicators of the Group comparing 3 months of 2022 and 2021:

Financial results for 3 months of 2022Change, compared to 3 months of 2021Adjusted* results for 3 months of 2022 Change, compared to 3 months of 2021
Revenue17.9 million EUR+14.1%17.9 million EUR+14.1%
Net profit (loss)-2.8 million EUR+6.3 million EUR1.4 million EUR+1.4 million EUR
EBITDA8.4 million EUR+15.5%8.4 million EUR+15.5%

Main financial indicators of the Company comparing 3 months of 2022 and 2021:

Financial results for 3 months of 2022Change, compared to 3 months of 2021Adjusted* results for 3 months of 2022Change, compared to 3 months of 2021
Revenue17.1 million EUR+14.5%17.1 million EUR+14.5%
Net profit (loss)-3.1 million EUR+6.1 million EUR1.1 million EUR+1.0 million EUR
EBITDA8.0 million EUR+14.3%8.0 million EUR+14.3%

* Adjusted financial figures are recalculated and presented by eliminating from net profit (loss) the following amounts: (1) the impact of unrealised foreign currency exchange rates arising from IFRS 16 requirements, (2) respective impact of deferred income tax arising from unrealised foreign currency exchange rates gains/losses and (3) impact of financial derivatives.

Management comment:

During three months of 2022, the same as during 2021, the Group‘s and the Company‘s net profit (loss) was significantly affected by unrealized fluctuations of currency exchange rates. The unrealized impact of exchange rates arose from the 1 January 2019 under the requirements of IFRS 16 “Lease”, according to which the Company recognises finance lease obligations and the major part of them is denominated in US dollars. Whereas all US dollar denominated lease liabilities relate to LNG terminal, the effect of unrealized exchange rate is reflected in the regulated segment.

Regulated LNG activities revenue for Q1 of 2022 is EUR 10.2 million and is higher by EUR 1.3 million or 14.3% compared to the same period of 2021 (EUR 8.9 million). The main reasons: (1) higher revenue from AB Amber Grid by EUR 0.5 million due to recalculated actual consumption capacities of previous period (2022 – EUR 1.1 million, 2021 – EUR 0.6 million) and revenue related to the natural gas consumer’s liability for previous periods after the court decision in amount of EUR 1.1 million; 2) EUR 0.2 million lower regasification revenue for the Q1 of 2022 vs 2021; 3) EUR 0.1 million lower revenue from the fixed part of LNG regasification service fee has been collected during Q1 of 2022 compared to the same period of 2021.

Revenue from commercial LNG activities for Q1 of 2022 is EUR 1.3 million and is EUR 0.1 million lower compared to the same period in 2021 (EUR 1.4 million). Commercial LNG activities consist of business development projects including LNG terminal operator services provided at the Port of Açu terminal in Brazil and LNG reloading station in Klaipėda.

Revenue from oil terminals for Q1 of 2022 (EUR 6.4 million) is EUR 1.0 million higher compared to the same period in 2021 (EUR 5.4 million). The positive impact on the volumes of oil product cargo handling at Klaipėda Oil Terminal was due to the regional and global oil product tightness, soaring oil product prices, and increasing European refineries production demand. Demand for oil storage services remained low in the first quarter of 2022 due to continuing backwardation tendencies in markets, which was reinforced by the declining level of oil product inventories in the region, especially for diesel.   However, transshipment of ethanol, petrochemicals, and bitumen intensified. The diversification of petroleum product handling was enhanced by the handling of a new product, crude oil of Lithuanian origin. The first batch of this cargo was accumulated and loaded on board in the first quarter.


  1. Condensed Consolidated and Separate Financial Statements of AB Klaipėdos nafta for 3 months period ended 31 March 2022.
  2. Presentation of the unaudited financial results of the Group for Q1 of 2022.

Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form